AbbVie, a pharmaceutical company, and Anima Biotech, a biotechnology research company, formed a joint venture. Financial terms were not disclosed. "Anima's differentiated approach in the field of small molecule mRNA drugs combines phenotypic screening with AI-driven elucidation of the mechanisms of action. The power of our mRNA Lightning platform is validated by our multiple partnerships and a growing internal pipeline. We are excited to partner with AbbVie, a recognized global leader in Oncology and Immunology, and are looking forward to start working with their excellent scientific team in a close collaboration," Yochi Slonim, Anima Co-Founder and CEO.